From Nasdaq_FREQ:

In the biotech industry, small drugmakers are seeing their shares skyrocketing. Madrigal Pharmaceuticals has a promising candidate, resmetirom, for treating NASH, with an estimated $108 billion market by 2030. The FDA should decide by March. However, the small biotech, having no profits or sales, also has substantial downside risks. Viking Therapeutics, also targeting NASH treatments, with VK2735 and VK2809 in phase 2 studies, has potential for entering a rapidly growing weight-loss market. But the uncertainty requires caution before considering investment. Both companies should be on the radar for potential investors considering long-term investment strategies.



Read more: 2 Stocks That Could Soar This Year: Are They Buys?